Table 3 Comparison between patients with secondary renal outcome and those without
From: Long-term prognosis of clinically early IgA nephropathy is not always favorable
Variables | Renal outcome (-) | Renal outcome (+) | P–value |
|---|---|---|---|
N | 104 | 14 | |
Age at the time of biopsy (years) | 26 (19–37) | 27 (25–35) | 0.640 |
Sex (male, %) | 47/104 (45.2%) | 3/14 (21.4%) | 0.148 |
Body mass index (kg/m2) | 21.6 (19.9–23.5) | 21.7 (20.5–23.1) | 0.749 |
Systolic blood pressure (mmHg) | 120 (110–126) | 115 (110–130) | 0.990 |
Serum creatinine (mg/dL) | 0.90 (0.80–1.04) | 0.80 (0.70–0.90) | 0.016 |
eGFR (ml/min/1.73 m2) | 86.4 (74.9–105.6) | 93.0 (82.5–113.2) | 0.142 |
Albumin (g/dL) | 4.1 (3.9–4.4) | 3.9 (3.5–4.3) | 0.038 |
Proteinuria (g/day) | 0.25 (0.10–0.40) | 0.28 (0.10–0.41) | 0.680 |
WHO grade | 2.0 (2.0–2.0) | 2.5 (2.0–3.0) | 0.047 |
Global sclerosis ≥ 10% | 32/104 (30.8%) | 8/14 (57.1%) | 0.214 |
Segmental sclerosis ≥ 10% | 9/104 (8.7%) | 5/14 (35.7%) | 0.012 |
Cresent | 10/104 (9.6%) | 1/14 (7.1%) | 1.000 |
Mesangial proliferation | 15/103 (14.6%) | 3/14 (21.4%) | 0.450 |
Interstitial fibrosis | 8/103 (7.8%) | 5/14 (35.7%) | 0.009 |
Interstitial inflammation | 1/103 (1.0%) | 0/14 (0.0%) | 1.000 |
Tubular atrophy | 11/103 (10.7%) | 5/14 (35.7%) | 0.024 |
RAS blockade (N, %) | 48/103 (45.4%) | 12/14 (84.6%) | 0.009 |